Format

Send to

Choose Destination
J Am Acad Dermatol. 2002 Jun;46(6):945-7.

Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent.

Author information

1
Department of Dermatology, Columbia-Presbyterian Medical Center, New York, New York, USA.

Abstract

Invasive aspergillosis is uncommon in immunocompetent hosts but is the second most common opportunistic fungal infection in immunocompromised patients. There has been a dramatic increase in the incidence of life-threatening aspergillosis during the past 2 decades, and the morbidity and mortality of these infections despite antifungal therapy remain unacceptably high. We describe a patient with amphotericin B-resistant Aspergillus flavus successfully treated with caspofungin, an agent belonging to a new class of antifungal drugs. Caspofungin shows great promise in the treatment of invasive aspergillosis.

PMID:
12063497
DOI:
10.1067/mjd.2002.120627
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center